TrademarkDir
OXIDIEN PHARMACEUTICALS
DEAD

Serial Number

88429708

Owner

CAPTOZYME INC.

Attorney

Amber N. Davis

Filing Date

May 14, 2019

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

OXIDIEN PHARMACEUTICALS Trademark

Serial Number: 88429708

OXIDIEN PHARMACEUTICALS is a trademark filed by CAPTOZYME INC. on May 14, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

CAPTOZYME INC. (7 trademarks)

1622 NW 55TH PLACE
GAINESVILLE, FL 32653

Entity Type: 03

OXIDIEN PHARMACEUTICALS, LLC (3 trademarks)

747 SW 2nd Avenue, Suite 240
GAINESVILLE, FL 32601

Entity Type: 16

Trademark Details

Filing Date

May 14, 2019

Registration Date

Not Registered

Published for Opposition

August 13, 2019

Goods & Services

Pharmaceutical preparations, substances and products for use in nephrology and urology, namely, for the treatment and prevention of kidney-related disease such as kidney stones, hyperoxaluria, hyperoxalemia, and chronic kidney disease

Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval

Pharmaceutical products development; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development; scientific and technological services, namely, research and development of new products for others, scientific research in the field of pharmaceutics, scientific laboratory services; medical and pharmacological research services, namely, conducting clinical trials for others in the field of pharmaceutical preparations, drugs; natural science services, namely, biological research, chemical analysis of industrial and clinical fluids; medical and scientific research; pharmaceutical research and development; and clinical testing, namely, conducting clinical trials for others in the field of pharmaceutical preparations, drugs; product development of probes, reagents and bioassays for industrial and scientific purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 14, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 14, 2022 ABN6
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 20, 2022 ASGN
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 12, 2022 EXRA
SOU EXTENSION 5 GRANTED
Apr 11, 2022 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 11, 2022 AITU
SOU EXTENSION 5 FILED
Apr 4, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 4, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 24, 2021 EXRA
SOU EXTENSION 4 GRANTED
Sep 22, 2021 EX4G
SOU EXTENSION 4 FILED
Sep 22, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 22, 2021 EEXT
ASSIGNED TO EXAMINER
Jun 14, 2021 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 13, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 13, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 13, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2021 EXRA
SOU EXTENSION 3 GRANTED
Mar 1, 2021 EX3G
SOU EXTENSION 3 FILED
Mar 1, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 1, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2020 EXRA
SOU EXTENSION 2 GRANTED
Oct 1, 2020 EX2G
SOU EXTENSION 2 FILED
Oct 1, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 1, 2020 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 17, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 17, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 17, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 17, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 17, 2020 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 7, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 7, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 7, 2020 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 4, 2020 EXRA
SOU EXTENSION 1 GRANTED
Apr 2, 2020 EX1G
SOU EXTENSION 1 FILED
Apr 2, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 2, 2020 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 1, 2020 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 8, 2019 NOAM
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 2, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 2, 2019 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2019 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2019 NONP
ASSIGNED TO LIE
Jul 2, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 24, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 24, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 24, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 24, 2019 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 8, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jun 8, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jun 8, 2019 CNRT
ASSIGNED TO EXAMINER
Jun 8, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 3, 2019 NWOS
NEW APPLICATION ENTERED
May 17, 2019 NWAP

Related Trademarks

More from this Owner

OXIDIEN PHARMACEUTICALS

OXIDIEN PHARMACEUTICALS

OXIDIEN PHARMACEUTICALS

OXIDIEN PHARMACEUTICALS

NEPHURE

NEPHURE

NEPHURE

NEPHURE

NEPHURE

NEPHURE

NEPHURE

NEPHURE